APOE and Alzheimer disease: APOE4 carriers with AD show earlier Aβ accumulation, earlier clinical disease onset, faster disease progression, heavier plaque burden, and increased brain atrophy, while APOE2 carriers with AD have later Aβ deposition, later clinical onset, and increased longevity (1).